Tag: dextenza

June 29, 2018

Ocular Therapeutix Announces NDA Resubmission of DEXTENZA

Ocular Therapeutix (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions...
April 29, 2018

5 Top Weekly NASDAQ Biotech Stocks: Eleven Biotherapeutics Up 45 Percent

Eleven Biotherapeutics, EyePoint Pharmaceuticals, Avid Bioservices, Cerecor and Celldex were last week's top gainers on the NASDAQ.
April 1, 2018

5 Top NASDAQ Biotech Stocks: Cardiome on Top

Cardiome, Avid, XBiotech, Fennec and Compugen were last week's five top-gaining NASDAQ biotech stocks. See what moved their share prices.
March 18, 2018

5 Top NASDAQ Biotech Stocks: Second Sight Medical on Top

Second Sight, Juniper, Athersys, Aptose and ArQule were last week's five top-gaining NASDAQ biotech stocks. See what moved their share...
March 4, 2018

5 Top NASDAQ Biotech Stocks: Tenax on top with a 51.94 Percent Increase

This past week the NASDAQ Biotechnology Index increased by 4.15 percent reaching 3,501.80 points in the last week—nearly equal to...
November 20, 2016

5 Top NASDAQ Biotech Stocks: Ocular Therapeutix Gains Near 60 Percent

The week's top gainer was Ocular Therapeutix, followed by Cara Therapeutics, Immunomedics, Rockwell Medical and Array BioPharma.
November 14, 2016

Ocular Therapeutix™ Announces Successful Topline Results from Phase 3 Clinical Trial of DEXTENZA™

Ocular Therapeutix today announced positive topline results from its phase 3 clinical trial of DEXTENZA™ (dexamethasone insert) 0.4 mg, for...